Aleniglipron
Phase 3Small molecule
Aleniglipron is one of 68 small molecule programs targeting Obesity. It is currently in Phase 3.
2
Indications
5
Total Trials
3
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
176 competitors in Obesity
#DrugCompanyPhaseTrials
1Decadron
AAspen Global Incorporated
Phase 3
Maridebart Cafraglutide
AmgenPhase 3
Berobenatide
PfizerPhase 3
NNC0487-0111
Novo NordiskPhase 3
Zenagamtide
Novo NordiskPhase 3
Naltrexone-Bupropion Combination
CCurrax Pharmaceuticals
Phase 3
PF-08653944
PfizerPhase 3
Ribupatide
KKailera
Phase 3
Aleniglipron
GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
Survodutide
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Obesity2 trials
A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Multiple Maintenance Doses of Oral Once Daily Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Recruiting·GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics·Phase 3·NCT07654374·1,100 enrolled
A Randomized, Double-Blind, Placebo-Controlled, Pivotal Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of Multiple Maintenance Doses of Once Daily Oral Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and a Weight-Related Comorbidity
Recruiting·GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics·Phase 3·NCT07654361·3,600 enrolled
Hepatic Impairment1 trial
Obese1 trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety and Tolerability of Aleniglipron in Adult Participants With Type 2 Diabetes Mellitus Living With Obesity or Overweight
Completed·GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics·Phase 2·NCT07400588·58 enrolled
Obesity, Overweight, or Chronic Weight Management1 trial
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) With at Least One Weight-related Comorbidity
Completed·GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics·Phase 2·NCT06693843·230 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aleniglipron. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details